NKp46-Binding Variable Regions for Targeted NK Cell Lysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for proteins with new and well-defined mechanisms of action that can enhance NK cell cytotoxicity against target cells, as existing bispecific antibodies primarily focus on linking CD3 to tumor-associated antigens and lack specificity for NK cells.
Innovation Solution
Development of antigen binding domains that bind both human and non-human primate NKp46 polypeptides, allowing NK cells to be directed to lyse target cells by incorporating variable regions into single chain or multimeric proteins, which can activate NK cells through NKp46 signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional bispecific antibodies link CD3 to tumor-associated antigens, then T-cell activation is achieved, but NK cell specificity is lost
Solution Approach 1:
The patent segments the bispecific antibody into distinct variable regions, with one arm specifically targeting NKp46 on NK cells and the other arm targeting tumor-associated antigens. This segmentation allows independent optimization of each binding interaction, ensuring NK cell specificity while maintaining tumor targeting capability.
Solution Approach 2:
The patent applies local quality by designing the first variable region with specific affinity characteristics for NKp46 while the second variable region maintains affinity for tumor antigens. This localized functional differentiation ensures that NK cells are specifically recruited without compromising the overall therapeutic mechanism.
2Adaptability or versatility
If full-length IgG1 antibodies mediate ADCC via CD16, then NK cell cytotoxicity is enhanced, but mechanism diversity is limited
Solution Approach 1:
The patent extracts the essential NK cell recruitment function from the full-length IgG1 structure by utilizing antibody variable regions that specifically bind NKp46. This extraction allows the creation of simplified protein formats (such as scFv or Fab fragments) that retain NK cell targeting capability while reducing overall molecular complexity and enabling diverse structural configurations.
Solution Approach 2:
The patent creates a universal NK cell targeting module (the NKp46-binding variable region) that can be integrated into multiple different protein formats and bispecific configurations. This universal module enables the same NK cell recruitment mechanism to be applied across various antibody architectures, including different chain arrangements and domain configurations.
3Reliability
If variable regions are designed for high NKp46 affinity, then NK cell activation is enhanced, but off-target binding may increase
Solution Approach 1:
The patent optimizes binding parameters by carefully tuning the affinity of the NKp46-variable region through sequence selection and engineering. By adjusting binding strength parameters within an optimal range, the patent achieves sufficient NK cell activation while minimizing off-target effects. The same approach is applied to the tumor antigen-binding arm to ensure selective tumor cell recognition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed proteins effectively redirect NK cells to lyse target cells, including cancer cells, by activating NK cells through NKp46, overcoming the limitations of conventional antibodies and enhancing cytotoxicity.
Implementation Method 1
an antigen binding domain that binds a human NKp46 polypeptide
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.